Squamous Cell Cancer of the Cervix, Immune Senescence and HPV: Is Cervical Cancer an Age-Related Neoplasm ?

1993 ◽  
pp. 13-26 ◽  
Author(s):  
Jeanne Mandelblatt
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Immune Senescence ◽  
Age Related ◽  
Cancer Of The Cervix

Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-α and 13-cis-retinoic acid

1996 ◽  
Vol 7 (7) ◽  
pp. 800-804 ◽  
Author(s):  
Surintip Piamsomboon ◽  
Wichai Termrungruanglert ◽  
Andrzej P Kudelka ◽  
Creighton L Edwards ◽  
Ralph S Freedman ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Interferon Α ◽  
Cancer Of The Cervix

Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix

2002 ◽  
Vol 20 (4) ◽  
pp. 966-972 ◽  
Author(s):  
R. Pearcey ◽  
M. Brundage ◽  
P. Drouin ◽  
J. Jeffrey ◽  
D. Johnston ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Lymph Node Involvement ◽  
Phase Iii ◽  
Gynecology And Obstetrics ◽  
Significant Difference ◽  
Cancer Of The Cervix

PURPOSE: To test the hypothesis that cisplatin (CDDP) administered concurrently with standard radiotherapy (RT) would improve pelvic control and survival in patients with advanced squamous cell cancer of the cervix. PATIENTS AND METHODS: A total of 259 patients with International Federation of Gynecology and Obstetrics stage IB to IVA squamous cell cervical cancer with central disease ≥ 5 cm or histologically confirmed pelvic lymph node involvement were randomized to receive RT (external-beam RT plus brachytherapy) plus weekly CDDP chemotherapy (40 mg/m2) (arm 1) or the same RT without chemotherapy (arm 2). RESULTS: A total of 253 patients were available for analysis. Median follow-up was 82 months. No significant difference was found in progression-free survival (P = .33). No significant difference in 3- and 5-year survival rates was found (69% v 66% and 62% v 58%, respectively; P = .42). The hazard ratio for survival (arm 2 to arm 1) was 1.10 (95% confidence interval, 0.75 to 1.62). CONCLUSION: This study did not show a benefit to either pelvic control or survival by adding concurrent weekly CDDP chemotherapy in a dose of 40 mg/m2 to radical RT as given in this trial. Careful attention to RT details is important for achieving optimum outcome for patients with this disease.

Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.

1987 ◽  
Vol 5 (11) ◽  
pp. 1791-1795 ◽  
Author(s):  
D S Alberts ◽  
R Kronmal ◽  
L H Baker ◽  
D L Stock-Novack ◽  
E A Surwit ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Mitomycin C ◽  
Phase Ii ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Response Rates ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Cancer Of The Cervix

Cisplatin has proven to be the most active single agent in the treatment of metastatic and recurrent squamous cell cancer of the cervix. In a previous southwest Oncology Group (SWOG) pilot study, the addition of cisplatin to a mitomycin-C, vincristine, and bleomycin (MVB) regimen resulted in a relatively high percentage of durable complete responses. To gain more experience with cisplatin-based chemotherapy regimens, the SWOG initiated a phase II randomized trial of cisplatin, mitomycin-C plus cisplatin (MC), and MVB plus cisplatin (MVBC) in 119 patients with advanced squamous cell cancer of the cervix and no prior chemotherapy exposure. Because of slow patient accrual early in the trial, the cisplatin arm was discontinued. Five patients were declared ineligible according to protocol criteria. The three treatment groups were relatively well matched for age, prior radiation exposure, and sites of measurable disease. The overall objective response rates for cisplatin, MC, and MVBC treated patients were 33%, 25%, and 22%, respectively. Median response durations were greater than 6 months. Median survival durations associated with cisplatin, MC, and MVBC treatment were 17.0, 7.0, and 6.9 months, respectively. There were no drug-related deaths. Severe or life-threatening leukopenia and thrombocytopenia were observed in 18% to 24% of patients treated with MVBC and MC, but in none of those receiving cisplatin alone. We conclude that the low response rates and short durations of both response and survival observed in patients randomized to the two chemotherapy combinations suggest that only enhanced toxicity was gained through the addition of mitomycin-C or MVB to cisplatin in patients with advanced cervix cancer.

Association of Casp3 microRNA Target Site (1049216) SNP With the Risk and Progress of Cervical Squamous Cell Carcinoma

2017 ◽  
Vol 27 (2) ◽  
pp. 206-213 ◽  
Author(s):  
Xin Guo ◽  
Zhiming Dong ◽  
Sohsuke Yamada ◽  
Yuanyuan Li ◽  
Yanli Guo ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell ◽  
Caspase 3 ◽  
Mononuclear Cells ◽  
Luciferase Activity ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Target Site ◽  
Luciferase Reporter ◽  
Tumor Tissues

ObjectiveIn the present study, we investigated the relationship between the single-nucleotide polymorphism (SNP) of caspase-3 rs1049216 (C > T), a miRNA target site, and the risk and progression of cervical cancer.Materials and MethodsUsing polymerase chain reaction–restriction fragment length polymorphism, we evaluated the genotype and distribution of caspase-3 rs1049216 in 515 patients with cervical squamous cell cancer and 415 controls. In additional experiments, we transfected luciferase reporter plasmids carrying T or C allele and/or miRNA mimics into the human cervical cell lines (HeLa and C-33A) to analyze its roles in the regulation of caspase-3 expression. By immunohistochemistry, the protein level of caspase-3 expression was examined in tumor tissues from 515 patients with cervical squamous cell cancer.ResultsWe found that the TT genotype of caspase-3 rs1049216 conferred a significantly decreased risk of cervical cancer (adjusted odds ratio, 0.35; 95% confidence interval, 0.154–0.581) and may be associated with the progression of this cancer. Although the expression of caspase-3 in the TT genotype was higher than that in CC/CT genotype in peripheral blood mononuclear cells and tumor tissues. Additional luciferase analysis showed that the rs1049216 variant T allele was associated with significantly higher luciferase activity, compared with the C allele in the transfected cells, and when cotransfected with miRNAs, miRNA-181a could downregulate the luciferase activity in the cells that transfected the construct containing C allele, compared with T allele, which had not happened in the presence of other miRNAs selected.ConclusionsThese data indicate that through upregulating the expression of caspase-3, the TT genotype of caspase-3 rs1049216 can be associated with not only the risk of cervical cancer but also the progression of this cancer.

Highly Differentiated Keratinizing Squamous Cell Cancer of the Cervix

2001 ◽  
Vol 25 (10) ◽  
pp. 1310-1315 ◽  
Author(s):  
Carl Morrison ◽  
Francesco Catania ◽  
Paul Wakely ◽  
Gerard J. Nuovo
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Cancer Of The Cervix
Sign in / Sign up

Export Citation Format

Share Document